Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT

作者：Murata M^*; Nishida T; Taniguchi S; Ohashi K; Ogawa H; Fukuda T; Mori T; Kobayashi H; Nakaseko C; Yamagata N; Morishima Y; Nagamura Inoue T; Sakamaki H; Atsuta Y; Suzuki R; Naoe T

来源：Bone Marrow Transplantation, 2014, 49(3): 355-360.

DOI：10.1038/bmt.2013.180

• idiopathic myelofibrosis
• hematopoietic SCT
• donor source
• engraftment
• survival

To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n= 19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n= 11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) %26gt;= 2 (vs PS 0-1) predicted a lower OS (P= 0.044), and RBC transfusion %26gt;= 20 times before transplantation (vs transfusion %26lt;= 9 times) showed a trend toward a lower OS (P= 0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.

• 出版日期2014-3
• 单位河北医科大学